Issues |
Contents Summary |
Attachment |
Issue 34 - May 2022 - Part 1 May 2022 - Part 2
|
Part 1
- New antimicrobial prescribing guidance
- Ranitidine – licence suspended
- COPD training sessions
- Saxenda® (Liraglutide 6mg/ml Injection) – not for primary care prescribing
- South East Lipid Management Webinar
- Polypharmacy: Understanding the data webinar (24 May)
- Prescribing Midazolam for end of life care
- Local area updates – east Kent
Part 2
- Chlordiazepoxide Librium warning
- The Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update, Pregabalin, Denosumab
|
Supply Shortage Alert |
Issue 35 - June 2022 - Part 1 June 2022 - Part 2 June 2022 - Part 3
|
Part 1
- Kent and Medway Position Statement and Risk Mitigation Principles for Anticoagulant prescribing
- FAO GPs and Community Pharmacists: Intelligence Update Report from Sussex Police
- June Shortage article
- Sim 4 Mental Health
Part 2
- The carbon footprint of inhalers
- Reminder: Deadline for Practices to submit returns for MOS 2021/22
- We would like to hear from YOU!
Part 3
- Opportunity to Input into Review of UTI Diagnostic Flowchart
- Information for all General Practitioner and Independent Prescriber colleagues from Maidstone and Tunbridge Wells NHS Trust
- Kent & Medway CCG Medicines Optimisation Team NICE News Bimonthly - June 2022
- FAO Community Pharmacy and GP Dispensing Practices
- Kent and Medway Medicines Optimisation Scheme for 2022-2024
|
|
Issue 36 - July 2022 - Part 1 July 2022 - Part 2
|
Part 1
- Medicines Optimisation System Working at its best – NHS Kent and Medway AND Kent Community Health Foundation Trust (KCHFT) Pharmacy Teams shortlisted for HSJ Patient Safety Awards 2022!
- Good Practice News
- Shortages Summary July 2022
- NICE guidance for Acute Otitis Media
- New NICE guideline: Medicines associated with dependence or withdrawal symptoms (useful for the dependence forming medicines project in the MOS!)
- A reminder for primary care prescribers – Hypomagnesaemia associated with Proton Pump Inhibitors (PPIs)
- Reminder of Potassium Permanganate CAS Alert[1]Inadvertent Oral Administration of Potassium Permanganate
- Asthma and Nebulisers
- Dapagliflozin for treating Chronic Kidney Disease (CKD)
- Kent and Medway Managing Deterioration Management tool – RESTORE2
- Best Practice Guidance for Care Homes
Part 2
- MHRA Drug Safety Update June 2022
- Sentinel Plus Project
|
|
Issue 37 - August 2022 |
- Guidance for Multicompartmental Aids MCAs/Dosette Boxes
- Shortages Summary August 2022
- National Patient Safety Alert: Mexiletine
- MHRA Drug Safety Update
- MHRA Class 4 Medicines Defect Information: Novo Nordisk Limited, NovoRapid® FlexTouch® 100 units/ml, Saxenda® FlexTouch® (liraglutide) 6mg/ml, EL(22)A/33
- CPD conference on Controlled Drugs: Ensuring the Safer Management
- Important Product Supply Information: Shortec Oral Solution
- NICE News Bimonthly - August 2022
- Cow’s Milk Allergy Feed
- Tobacco Industry Lobbying
|
|
Issue 38 - September 2022 |
- Clozapine Safety
- Product Discontinuation: Seroxat (paroxetine hydrochloride) 20mg/10ml oral suspension
- Product Discontinuation: Insuman Infusat 100units/ml solution for injection 3.15ml cartridges (Sanofi) 5 cartridge
- Amoxicillin Prescribing and Duration
- Reminder: Best Practice Guidance for Care Homes
- Medicines Optimisation MHRA Drug Safety Update – August 2022 (for September 2022 MO Newsletter)
- Shortages Summary September 2022
- Medicine Supply Notification – Temazepam 10mg and 20mg tablets – and Local Recommendations
- MHRA – Class 4 Medicines Defect Information: Rosuvastatin 5 mg, 10 mg and 20 mg film-coated tablets EL (22)A/35
- MHRA – Class 4 Medicines Defect Information: Rosemont Pharmaceuticals Ltd, Atorvastatin 4mg/ml Oral Suspension & Sildenafil 10mg/ml Oral Suspension, EL (22)A/39
- MHRA – Class 2 Medicines Recall: Dysport 500 Units Powder for Solution for Injection, EL (22)A/36
- MHRA – Class 2 Medicines Recall: Novartis Pharmaceuticals UK, Sandimmum Oral Soultion, EL (22)A/40
|
|
Issue 39 - October 2022 |
- Guidance on NHS patients who wish to pay for additional private care
- Colchicine Prescribing
- Kent and Medway Position Statement and Risk Mitigation Principles for Anticoagulant Prescribing
- Ardens Long Term Conditions training Webinar
- Medicines Optimisation MHRA Drug Safety Update – September 2022 (for October 2022 MO Newsletter)
- Shortages Summary September 2022
- Medicine Supply Notifications: Nafarelin, Dulaglutide, Semaglutide and Dioralyte
- NICE News
- Asthma Inhalers and the Environment Patient Decision Aid (NG80)
- MHRA Anti-epileptic drugs: Advice on switching between manufacturer’s products.
- World Anti-Microbial Awareness Week (WAAW)
- Revised SPC: Forxiga (Dapagliflozin) film coated tablets
- PrescQipp Award Success
- CPCS request for Support from practices
- Pharmacy Technician Day- 18th October 2022
|
GLP1 Supply Shortage Statement |
Issue 40 - November 2022 |
- Reminder on the Prescribing of Sodium Valproate safely in Women and Girls
- Notification of product name change: Carefine Insulin Pen Needles to Greenfine Insulin Pen Needles
- SPS Medicines Advice Service Information
- Medicines Optimisation MHRA Drug Safety Update – Oct 2022
- Direct oral anticoagulants (DOAC) infographic
- Product Discontinuation: FreeStyle Libre 1
- November Shortages
- Serious Shortage Protocols: Estraderm MX® 50mcg and 75mcg patches
- Discontinuation of Stemetil 5mg/5ml Syrup
- MHRA Class 4 Medicines Defect Information: Venlafaxine XL 300 mg prolonged-release tablets
|
|
Issue 41 - December 2022 |
- HSJ Awards Success
- OTC prescribing
- COPD inhaler guidance reminder
- Discontinuation of Stemetil 5mg/5ml Syrup
- Asthma and nebulisers
- All Ranitidine products – license suspended
- Shortages Summary December 2022
- MHRA Updates
- NICE News December 2022
|
Supply Shortage Alert |
Issue 42 - January 2023 |
- Safety considerations with Metolazone preparations
- Over the counter medicines resources
- IT Support Ardens / EMIS
- MHRA Drug Safety Update
- Class 4 Medicines Defect Information: Galderma (U.K.) Limited, Epiduo 0.1% / 2.5% gel (45 g)
- Class 4 Medicines Defect Information: Albireo AB, Bylvay 1200 micrograms Hard Capsules, EL (23)A/01 Class 2 MHRA Recall – Dioctyl 100mg capsules
- Shortages
- Medicines Supply Notifications
- Serious Shortage Protocols
|
Supply Shortage Alert |
Issue 43 - February 2023 |
- Best Practice Guidance for Care homes
- Ozempic prescribing
- Urgent Field Safety Notice: FreeStyle LibreLink App for Android and FreeStyle Libre 3 App for Android (all versions)
- Celebrating Advanced Practice Conference 17th March 2023
- Shortages
- Medicines Supply Notification: Senokot® syrup and Senokot® 12 Years Plus syrup (both containing 7.5mg/5ml sennosides)
- NICE news February 2023
|
|
Issue 44 - March 2023 |
- Launch of the Kent and Medway ICB Medicines Optimisation Webpage
- Dexcom ONE transmitters on EMIS formulary
- Group A Strep (GAS) guidance update and impact on MOS sore throat audit.
- Inhaler Spacer Device Prescribing
- Salbutamol Prescribing
- MDI to DPI Switch
- MHRA Metolazone Drug Safety Update
- Clinical Fellow Scheme Application Information
- NICE CG181 Update
- KMPT Video Guides for Patients on Medicines Information
- Medicines Optimisation MHRA Drug Safety Update – Jan and Feb 2023
- MHRA Class 4 Defect Information- Venlafaxine 150mg,225mg and 300mg
- Shortages Summary March 2023
|
Supply Shortage Alert |
Issue 45 - April 2023 |
- Hormone Replacement Therapy (HRT) Prepayment Certificate (PPC)
- Chronic Pain Resources
- Non-Medical Prescribing and Controlled Drugs
- Reminder on Oral Hygiene Prescribing
- Antimicrobial Prescribing Survey
- Genomics Webinar: Aminoglycosides Pharmacogenetic Testing
- West Kent PCN Pharmacy Support Network Learning Session
- Medicines Optimisation MHRA Drug Safety Update – March 2023
- NICE News April 2023
- Shortages Summary April 2023
- MHRA - Class 4 Medicines Defect Information: Sandoz Limited, Co-amoxiclav 125/31.25mg/5ml, 250/62.5mg/5ml powder for oral suspension, EL (23)A/14
|
Supply Shortage Alert |